Metropolitan Life Insurance Co. NY lessened its holdings in shares of Humana Inc (NYSE:HUM) by 61.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 28,295 shares of the insurance provider’s stock after selling 46,044 shares during the period. Metropolitan Life Insurance Co. NY’s holdings in Humana were worth $7,019,000 at the end of the most recent reporting period.
Other large investors have also made changes to their positions in the company. Fieldpoint Private Securities LLC purchased a new position in shares of Humana during the third quarter valued at approximately $115,000. American Beacon Advisors Inc. purchased a new stake in shares of Humana in the fourth quarter valued at approximately $122,000. ClariVest Asset Management LLC purchased a new stake in shares of Humana in the third quarter valued at approximately $144,000. YorkBridge Wealth Partners LLC boosted its holdings in shares of Humana by 99.0% in the fourth quarter. YorkBridge Wealth Partners LLC now owns 597 shares of the insurance provider’s stock valued at $159,000 after purchasing an additional 297 shares during the period. Finally, Daiwa SB Investments Ltd. boosted its holdings in shares of Humana by 44.9% in the fourth quarter. Daiwa SB Investments Ltd. now owns 710 shares of the insurance provider’s stock valued at $176,000 after purchasing an additional 220 shares during the period. Institutional investors and hedge funds own 97.85% of the company’s stock.
HUM has been the subject of a number of research reports. Cantor Fitzgerald reiterated a “hold” rating and issued a $230.00 price target on shares of Humana in a report on Tuesday, December 5th. Cowen reiterated a “buy” rating and issued a $285.00 price target on shares of Humana in a report on Wednesday, December 13th. ValuEngine lowered Humana from a “buy” rating to a “hold” rating in a report on Tuesday, December 19th. Goldman Sachs initiated coverage on Humana in a report on Wednesday, January 3rd. They issued a “buy” rating and a $305.00 price target for the company. Finally, Jefferies Group upgraded Humana from a “hold” rating to a “buy” rating and set a $221.00 price target for the company in a report on Friday, January 12th. Eight investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. Humana has a consensus rating of “Buy” and an average target price of $270.47.
Humana (NYSE:HUM) last posted its earnings results on Wednesday, February 7th. The insurance provider reported $2.06 earnings per share for the quarter, topping analysts’ consensus estimates of $2.00 by $0.06. The company had revenue of $13.19 billion during the quarter, compared to analyst estimates of $13.14 billion. Humana had a return on equity of 16.13% and a net margin of 4.55%. Humana’s revenue was up 2.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.34 earnings per share. equities analysts forecast that Humana Inc will post 13.81 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, April 27th. Stockholders of record on Friday, March 30th will be given a dividend of $0.50 per share. The ex-dividend date of this dividend is Wednesday, March 28th. This is an increase from Humana’s previous quarterly dividend of $0.40. This represents a $2.00 dividend on an annualized basis and a dividend yield of 0.73%. Humana’s dividend payout ratio is presently 9.59%.
Humana declared that its Board of Directors has initiated a share repurchase program on Thursday, December 14th that allows the company to buyback $3.00 billion in outstanding shares. This buyback authorization allows the insurance provider to repurchase shares of its stock through open market purchases. Shares buyback programs are typically an indication that the company’s management believes its stock is undervalued.
In other news, VP Timothy S. Huval sold 1,382 shares of the company’s stock in a transaction on Tuesday, December 19th. The stock was sold at an average price of $246.04, for a total transaction of $340,027.28. Following the transaction, the vice president now directly owns 11,557 shares of the company’s stock, valued at $2,843,484.28. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP Jody L. Bilney sold 7,054 shares of the company’s stock in a transaction on Monday, December 18th. The stock was sold at an average price of $247.89, for a total value of $1,748,616.06. Following the transaction, the senior vice president now directly owns 11,704 shares in the company, valued at $2,901,304.56. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 41,775 shares of company stock worth $11,169,845. Insiders own 0.60% of the company’s stock.
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc (NYSE:HUM).
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.